title: Serum human chorionic gonadotropin levels and thyroid hormone levels in gestational transient thyrotoxicosis: Is the serum hCG level useful for differentiating between active Graves' disease and GTT?
abstract: Gestational transient thyrotoxicosis (GTT) is defined as transient thyrotoxicosis caused by the stimulating effect of human chorionic gonadotropin (hCG) during pregnancy. We attempted to identify the serum hCG level that causes GTT, and we compared the serum hCG levels and thyroid hormone levels of GTT patients according to whether they had a background of thyroid disease. We also evaluated serum hCG as a parameter for differentiating between active Graves' disease (GD) and GTT. We reviewed the 135 cases of pregnant women who came to our hospital to be evaluated for thyrotoxicosis during their 7th to 14th week of pregnancy, and their serum hCG level was measured at that time. Among the 135 pregnant women with thyrotoxicosis; 103 of the women had GTT, and the other 32 women had active GD. There were no correlations between their serum hCG levels and free thyroid hormone levels. There were no significant differences in thyroid hormone levels or hCG levels among the GTT groups with different thyroid disease backgrounds; i.e., the GTT group without thyroid disease, GTT group with chronic thyroiditis, GTT group with non-functioning thyroid nodules, and GTT group with GD in remission. The serum hCG level of the GTT group was significantly higher than in the active GD group, but it was not a good parameter for differentiating between the two groups. The FT3/FT4 ratio of the active GD was significantly higher than in GTT group, and was a better parameter for differentiation.
authors.affiliation: Ito Hospital, Tokyo 150-8308, Japan.
authors.forename: Ai
authors.initials: A
authors.lastname: Yoshihara
authors.forename: Jaeduk Yoshimura
authors.initials: JY
authors.lastname: Noh
authors.forename: Koji
authors.initials: K
authors.lastname: Mukasa
authors.forename: Miho
authors.initials: M
authors.lastname: Suzuki
authors.forename: Hidemi
authors.initials: H
authors.lastname: Ohye
authors.forename: Masako
authors.initials: M
authors.lastname: Matsumoto
authors.forename: Yo
authors.initials: Y
authors.lastname: Kunii
authors.forename: Natsuko
authors.initials: N
authors.lastname: Watanabe
authors.forename: Nami
authors.initials: N
authors.lastname: Suzuki
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Kameda
authors.forename: Kiminori
authors.initials: K
authors.lastname: Sugino
authors.forename: Koichi
authors.initials: K
authors.lastname: Ito
mesh_terms: D000465:Algorithms; D006063:Chorionic Gonadotropin / Q000097:blood*; D003937:Diagnosis, Differential; D005260:Female; D006111:Graves Disease / Q000097:blood* / Q000150:complications / Q000175:diagnosis; D050031:Hashimoto Disease / Q000150:complications; D006786:Hospitals, Urban; D006801:Humans; D007564:Japan; D008499:Medical Records; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood*; D011261:Pregnancy Trimester, First; D012008:Recurrence; D012189:Retrospective Studies; D016606:Thyroid Nodule / Q000150:complications; D013966:Thyroiditis / Q000150:complications; D013971:Thyrotoxicosis / Q000097:blood* / Q000150:complications / Q000175:diagnosis; D013974:Thyroxine / Q000097:blood*; D014284:Triiodothyronine / Q000097:blood*; D055815:Young Adult
chemical_list: D006063:Chorionic Gonadotropin; D014284:Triiodothyronine; D013974:Thyroxine